Synergistic effect of adoptive T-cell therapy and intratumoral interferon γ-inducible protein-10 transgene expression in treatment of established tumors

Cellular Immunology

Volumn 217, Issue 1-2, 2002, Pages 12-22

  Huang, Hui ^a   Liu, YongQing ^a   Xiang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adenoviral vector; Adoptive T cell therapy; IP 10 gene therapy; Tumor immunity

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; PERFORIN; PROTEIN; PROTEIN 10; RECOMBINANT DNA; SELECTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSGENE;

ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES, C; CHEMOKINES, CXC; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOKINES; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; SIALOGLYCOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 0036435799     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-8749(02)00508-7     Document Type: Article

References (46)

1. G. Plautz, J. Touhalisky, S. Shu, Treatment of murine glioma by adoptive transfer of ex vivo activated tumor-draining lymph node cells, Cell. Immunol. 178 (1997) 101-107.
2. L. Peng, S. Shu, J. Krauss, Treatment of subcutaneous tumor with adoptively transferred T cells, Cell. Immunol. 178 (1997) 24-32.
3. H. Hu, W. Urba, B. Fox, Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile, J. Immunol. 161 (1998) 3033-3341.
4. H. Tanaka, H. Yoshizawa, Y. Yamaguchi, K. Ito, H. Kagamu, E. Suzuki, F. Gejyo, H. Hamada, M. Arakawa, Successful adoptive immunotherapy of murine poorly immunogenic tumors with specific effector cells generated from gene-modified tumor-primed lymph node cells, J. Immunol. 162 (1999) 3574-3582.
5. J. Kjaergaard, S. Shu, Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but require down-regulation of L-selectin expression, J. Immunol. 163 (1999) 751-759.
6. S. Rosenberg, P. Spiess, R. Lafreniere, A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science 233 (1986) 1318-1321.
7. A. Chang, H. Yoshizawa, K. Sakai, M. Cameron, V. Sondak, S. Shu, Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro, Cancer Res. 53 (1993) 1043-1050.
8. A. Chang, A. Aruga, M. Cameron, D. Sondak, B. Normolle, S. Shu, Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2, J. Clin. Oncol. 15(1997) 796-807.
9. M. Ogawa, K. Umehara, W. Yu, Y. Uekusa, C. Nakajima, T. Tsujimura, T. Kubo, H. Fujiwara, T. Hamaoka, A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for IL-12-induced tumor regression, Cancer Res. 59 (1999) 1531-1538.
10. S. Mukai, J. Kjaergaard, S. Shu, G. Plautz, Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy, Cancer Res. 59 (1999) 5245-5249.
11. B. Fisher, B. Packaj, E. Read, J. Carrasquillo, C. Carter, S. Topalian, S. Rosenberg, Tumor localization of adoptively transferred indium-111 labelled tumor infiltrating lymphocytes in patients with metastatic melanoma, J. Clin. Oncol. 7 (1989) 250-261.
12. B. Packaj, R. Sherry, J. Wei, J. Yannelli, C. Carter, S. Leitman, J. Carasquillo, S. Steinberg, S. Rosenberg, J. Yang, Localization of indium-111 labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy, Cancer 73 (1994) 1731-1737.
13. R. Jain, The next frontier of molecular medicine, delivery of therapeutics, Nat. Med. 4 (1998) 655-657.
14. S. Rosenberg, J. Yannelli, S. Topalian, D. Schwartzentruber, J. Weber, D. Parkinson, C. Seipp, J. Einhorn, D. White, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and IL-2, J. Natl. Cancer Inst. 86 (1994) 1159-1166.
15. T. Springer, Traffic signals for lymphocyte recirculation and leukocyte emigration, the multistep paradigm, Cell 76 (1994) 301-314.
16. S. Roth, M. Carr, T. Springer, C-C chemokines, but not the C-X-C chemokines IL-8 and interferon γ inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes, Eur. J. Immunol. 25 (1995) 3482-3488.
17. M. Baggiolini, B. Dewald, B. Moser, Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines, Adv. Immunol. 55 (1994) 97-179.
18. D. Taub, J. Oppenheim, Chemokines, inflammation, and the immune system, Ther. Immunol. 1 (1994) 229-246.
19. J.J. Oppenheim, C.O. Zachariae, N. Mukaida, K. Matsushima, Properties of the novel proinflammatory supergene 3intercrine3 cytokine family, Annu. Rev. Immunol. 9 (1991) 617-648.
20. J.F. Bazan, K.B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D.R. Greaves, A. Zlotnik, T.J. Schall, A new class of membrane-bound chemokine a with CX3C motif, Nature 385 (1997) 640-644.
21. J. Farber, Mig and IP-10, CXC chemokines that target lymphocytes, J. Leukocyte Biol. 61 (1997) 246-257.
22. N. Jenkins, J. Hedrick, A. Zlotnik, The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3, Proc. Natl. Acad. Sci. USA 95 (1998) 8205-8210.
23. K. Cole, C. Strick, T. Paradis, K. Ogborne, M. Loetscher, R. Gladue, W. Lin, J. Boyd, B. Moser, D. Wood, B. Sahagan, K. Neote, Interferon-inducible T cell α chemoattractant (I-TAC), a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3, J. Exp. Med. 187 (1998) 2009-2021.
24. A. Angiolilo, C. Sgadari, G. Tosato, A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12, Ann. N Y Acad. Sci. 795 (1996) 158-167.
25. + T cells and neutrophils expressing XCR1 receptors, J. Immunol. 167 (2001) 57-65.
26. Y. Liu, H. Huang, A. Saxena, J. Xiang, Intratumoral coinjection of two, Cancer Gene Therapy 9 (2002) 533-542.
27. P. Wright, R. Braun, L. Babiuk, S. Little-van den Hurk, T. Moyana, C. Zheng, Y. Chen, J. Xiang, Adenovirus-mediated TNF-α gene transfer induces significant tumor regression in mice, Cancer Biother. Radiopharm. 14 (1999) 49-57.
28. J. Xiang, T. Moyana, Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1, J. Cytokine Interferon Res. 20 (2000) 349-354.
29. H. Huang, F. Li, C. Cairns, J. Gordon, J. Xiang, Neutrophils and B lymphocytes express the XCR1 receptor and chemotactically respond to lymphotactin, Biochem. Biophys. Res. Commun. 281 (2001) 378-382.
30. T. Kataoka, N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, K. Nagai, Concanamycin A a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity, J. Immunol. 156 (1996) 3678-3686.
31. + cytotoxic T-cell-mediated pathogenesis during virus infection, Proc. Natl. Acad. Sci. USA 93 (1996) 14730-14735.
32. J. Xiang, Y. Chen, T. Moyana, Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer, Cancer Gene Ther. 7 (2000) 1023-1033.
33. C. Sgadari, A. Angiolillo, B. Cherney, S. Pike, J. Farber, L. Koniaris, P. Vanguri, P. Burd, N. Sheikh, G. Gupta, J. Teruya-Feldstein, G. Tosato, Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo, Proc. Natl. Acad. Sci. USA 93(1996) 13791-13796.
34. A. Allione, M. Consalvo, P. Nanni, P.L. Lollini, F. Cavallo, M. Giovarelli, M. Forni, A. Gulino, M.P. Colombo, P. Dellabona, Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineering with IL-2, IL-4, IL-6, Il-7, IL-10, TNF, GM-CSF and IFN gene or admixed with conventional adjuvants, Cancer Res. 54 (1994) 6022-6026.
35. S. Shresta, C. Pham, D. Thomas, T. Graubert, T. Ley, How do cytotoxic lymphoctes kill their targets?, Curr. Opin. Immunol. 10 (1998) 581-587.
36. G. Griffiths, Protein sorting and secretion during CTL killing, Semin. Immunol. 9 (1997) 109-115.
37. E. Rouvier, M. Luciani, P. Golstain, Fas involvement in calcium-independent T cell-mediated cytotoxicity, J. Exp. Med. 177 (1993) 195-200.
38. Y. Chen, P. Emtage, Q. Zhu, R. Foley, W. Muller, M. Hitt, J. Gauldie, Y. Wan, Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified den-dritic cells: Enhanced efficacy by cotransduction of gene encoding IL-12, Gene Ther. 8 (2001) 316-323.
39. + T cells in vivo, J. Immunol. 153 (1994) 5443-5446.
40. low cells promotes the generation of highly potent CD4 antitumor e3ector T lymphocytes, J. Immunol. 160 (1998) 3444-3452.
41. I. Narvaiza, G. Mazzolini, M. Barajas, M. Duarte, M. Zaratiegui, C. Qian, I. Melero, J. Prieto, Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy, J. Immunol. 164 (2000) 3112-3122.
42. + T cells infiltrated within cancer cell as a prognostic factor in human colorectal cancer, Cancer Res. 58 (1998) 3491-3494.
43. S. Mukai, J. Kjargaard, S. Shu, G. Plautz, Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficiency, Cancer Res. 59 (1999) 5245-5248.
44. P. Sields, C. Morland, M. Salmon, S. Qin, S. Hubscher, D. Adams, Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver, J. Immunol. 163 (1999) 6236-6243.
45. I. Narvaiza, G. Mazzolini, M. Barajas, M. Duarte, M. Zaratiegui, C. Qian, I. Melero, J. Prieto, Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy, J. Immunol. 164 (2000) 3112-3122.
46. P. Emtage, Y. Wan, M. Hitt, F. Graham, W. Muller, A. Zlotnik, J. Gauldie, Adenoviral vectors expressing lymphotactin and IL-2 or lymphotactin and IL-12 synergize to facilitate tumor regression in murine breast cancer models, Hum. Gene Ther. 10 (1999) 697-709.